ARCTURUS THERAPEUTICS HOLDINGS INC. Segment Reporting Other Item Amount
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Segment Reporting Other Item Amount of -$1.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for the quarter ending 2026-06-30 was -$1.76M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for the quarter ending 2026-03-31 was -$1.97M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for the quarter ending 2025-12-31 was -$2.23M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for the quarter ending 2025-09-30 was -$3.06M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for fiscal 2025 was -$10.48M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for fiscal 2024 was -$14.73M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for fiscal 2023 was -$48.48M, a 1814.29% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. segment reporting other item amount for fiscal 2022 was $2.83M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.76M 10-Q · filed 2026-08-06 | -$3.73M 10-Q · filed 2026-08-06 | -$5.96M derived: sum of 3 quarters · filed 2026-08-06 | -$9.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.97M 10-Q · filed 2026-05-07 | -$4.20M derived: sum of 2 quarters · filed 2026-05-07 | -$7.26M derived: sum of 3 quarters · filed 2026-05-07 | -$9.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$5.29M derived: sum of 2 quarters · filed 2026-03-03 | -$7.73M derived: sum of 3 quarters · filed 2026-08-06 | -$10.48M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$3.06M 10-Q · filed 2025-11-12 | -$5.50M derived: sum of 2 quarters · filed 2026-08-06 | -$8.25M 10-Q · filed 2025-11-12 | -$11.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.44M 10-Q · filed 2026-08-06 | -$5.19M 10-Q · filed 2026-08-06 | -$8.57M derived: sum of 3 quarters · filed 2026-08-06 | -$12.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.75M 10-Q · filed 2026-05-07 | -$6.14M derived: sum of 2 quarters · filed 2026-05-07 | -$9.97M derived: sum of 3 quarters · filed 2026-05-07 | -$13.88M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$7.22M derived: sum of 2 quarters · filed 2026-03-03 | -$11.13M derived: sum of 3 quarters · filed 2026-03-03 | -$14.73M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$3.83M 10-Q · filed 2025-11-12 | -$7.74M derived: sum of 2 quarters · filed 2025-11-12 | -$11.34M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$3.91M 10-Q · filed 2025-08-11 | -$7.50M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$3.60M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$48.48M 10-K · filed 2026-03-03 | |||
| 2022-12-31 | $2.83M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |